Phathom Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
PHAT$5.33+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Deficit
(in thousands, except share amounts)
| Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Capital | Deficit | Deficit | |
| Balance at December 31, 2024 | 68,518,238 | $6 | 19 | $1,009,425 | $(1,263,011) | $(253,580) |
| 401(k) matching contribution | 616,377 | — | — | 5,258 | — | 5,258 |
| Vesting of restricted stock units and performance stock units, net of employee tax obligations | 1,615,577 | — | — | (1,926) | — | (1,926) |
| Stock-based compensation | — | — | — | 28,719 | — | 28,719 |
| ESPP shares issued | 505,293 | — | — | 2,969 | — | 2,969 |
| Issuance of common stock from exercises of stock options | 163,540 | — | — | 1,638 | — | 1,638 |
| Net loss | — | — | — | — | (221,247) | (221,247) |
| Balance at December 31, 2025 | 71,419,025 | $6 | 19 | $1,046,083 | $(1,484,258) | $(438,169) |
| Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Capital | Deficit | Deficit | |
| Balance at December 31, 2023 | 57,970,044 | $5 | 19 | $855,921 | $(928,685) | $(72,759) |
| 401(k) matching contribution | 383,589 | — | — | 3,683 | — | 3,683 |
| Vesting of restricted stock units | 965,681 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 24,047 | — | 24,047 |
| ESPP shares issued | 375,381 | — | — | 2,401 | — | 2,401 |
| Issuance of common stock from exercise of stock options | 127,891 | — | — | 1,599 | — | 1,599 |
| Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net | 8,695,652 | 1 | — | 121,774 | — | 121,775 |
| Net loss | — | — | — | — | (334,326) | (334,326) |
| Balance at December 31, 2024 | 68,518,238 | $6 | 19 | $1,009,425 | $(1,263,011) | $(253,580) |
See accompanying notes
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.